Figure 4. MH-30 has synergistic anticancer effects in combination of cisplatin in melanoma-bearing mice. All mice treated as described in figure 3 were sacrificed on day 22 after B16F10 melanoma inoculation. (A) The tumor weight of each group was measured. (B) Photographs of melanoma solid tumors taken from all mice of each group. There were eighteen~twenty-two mice in each group. Data are presented as the Mean±SD. †p<0.001 compared with control group; *p<0.005 compared with only cisplatin treated group.
